Studying serum immunoglobulin levels in metabolic dysfunction-associated steatotic liver disease Hazem Abosheaishaa, Emad Ahmad Awad Hussein, Shereen Abou Bakr Saleh, Mahmoud Nassar, Abdulaziz Elmaradny, et al. Egyptian Liver Journal, 2026 Background Preliminary data have found an association between serum immunoglobulins and metabolic dysfunction-associated steatotic liver disease (MASLD). We conducted this study to further investigate the levels of serum immunoglobulins in MASLD without steatohepatitis and metabolic dysfunction-associated steatohepatitis (MASH). Methods One hundred participants were enrolled in the study and divided into two groups. In group A, 50 participants were diagnosed with MASLD without inflammation (steatohepatitis) based on clinical, laboratory, and radiological examinations. In Group B, 50 patients with MASH were diagnosed based on clinical and radiological features as well as elevated liver enzymes. In qualitative data, we used numbers and percentages to describe quantitative data, while for normally distributed quantitative data we calculated ranges, means, and standard deviations. The correlations were carried out using Pearson correlations for numerically normally distributed data and Spearman rho tests for numerically non-normally distributed and qualitative data, respectively. Results A statistically significant increase in ALT, AST, GGT, INR, and serum IgA group, along with a significant drop in platelets, albumin, IgG, and IgM was seen in the MASH group in comparison with the MAFLD group. IgA level was significantly higher in S-3, with no significant differences between S-1 and S-2. From all the immunoglobulins tested, IgG had a significantly perfect diagnostic performance in predicting the difference between MASLD and MASH. Conclusion This study showed a correlation between MASLD with and without MASH and immunoglobulin levels in the blood with IgA being significantly high in MASH; however, IgG and IgM are significantly high in NAFL. IgG had a perfect diagnostic performance in predicting the difference between MASH and MASLD from all the immunoglobulins tested.
Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials Ahmed Yasser Shaban, Ahmed Hassan, Sherif Eltawansy, Malak A. Hassan, Mariam Tarek Desouki, et al. Egyptian Heart Journal, 2026 Background Hypertension (HTN) and dyslipidemia are major risk factors for cardiovascular diseases. Recently, researchers have investigated the potential benefits of combining multiple medications in one bill to improve their metabolic and cardiovascular efficacy. Objectives We investigated a treatment approach that combines two antihypertensive medications with one statin. We aim to assess the safety and effectiveness of a triple therapy regimen consisting of angiotensin receptor blockers (ARBs) combined with amlodipine/rosuvastatin. We compared this triple therapy to dual therapy involving either ARBs/amlodipine or ARBs/rosuvastatin in patients with HTN and dyslipidemia. Methods We conducted systematic search in the following databases: Medline, Web of Science, Scopus, and Cochrane Library until August 2024. The main outcomes assessed were the variations in mean systolic blood pressure (mSBP), mean diastolic blood pressure (mDBP), and the percentage changes in LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) following an eight-week treatment period. Results Our analysis included seven randomized controlled trials (RCTs) which enrolled 1074 patients. Triple therapy revealed a significant reduction in mSBP (mean difference (MD): -4.06, 95% C.I. [-7.97: -0.15], p-value = 0.04), mDBP (MD: -5.45, 95% C.I. [-7.96: -2.93], p-value = < 0.0001), and LDL-C (MD: -50.10, 95% C.I. [-55.55: -44.64], p-value = < 0.001) compared to ARBs/amlodipine. Triple therapy significantly decreased mSBP (MD: −12.28, 95% C.I. [− 16.68: −7.88], p-value = < 0.001) and mDBP levels (MD: −6.48, 95% C.I. [-10.95: -2.01], p-value = 0.005) compared with ARBs plus rosuvastatin. There was no significant difference in secondary outcomes, including total adverse events, cerebrovascular adverse events, and adverse drug reactions. Conclusion Triple therapy has greater effectiveness in decreasing blood pressure in hypertensive patients with dyslipidemia compared to treatments involving ARBs combined with amlodipine or ARBs with rosuvastatin. Additionally, Triple therapy significantly improved lipid profiles compared to the ARB/amlodipine group. Our study lays the groundwork for developing a single-pill, triple-combination therapy. Further RCTs are necessary to confirm our findings.
Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021 Yi Deun Jeong, Seoyoung Park, Wonwoo Jang, Min Seo Kim, A Bhoomadevi, et al. Korean Journal of Internal Medicine, 2026 Background/Aims: This study aims to evaluate the global burden of adverse effects of medical treatment (AEMT) using data from the Global Burden of Disease Study (GBD) 2021.Methods: Data were extracted from the GBD 2021, covering 204 countries/territories from 1990 to 2021. AEMT was defined using ICD-9 and ICD-10 codes, encompassing complications from medical procedures, treatments, or healthcare exposures. Estimates were categorized into fatal and non-fatal outcomes and stratified by age, sex, year, and covariates, including the Socio-demographic Index (SDI). Mortality-incidence ratios (MIRs), defined as the ratio of mortality calculated by dividing the number of deaths by the total incident cases, were analyzed.Results: In 2021, the global age-standardized prevalence, incidence, disability-adjusted life years (DALYs), and mortality rates of AEMT were 11.48 (95% uncertainty interval [UI], 8.86–14.13), 150.44 (131.19–171.81), 64.19 (51.06–73.11), and 1.53 (1.29–1.68) per 100,000 population, respectively. DALY rates were highest in the early neonatal group (4,789.47 per 100,000 population [95% UI, 3,682.00–5,963.30]), while mortality rates followed a U-shaped pattern across age groups. In 2021, MIRs were highest at both ends of the age range: the early neonatal group (0.58 [95% UI, 0.55–0.58]) and the 95+ age group (0.05 [0.04–0.06]). This pattern was consistent across all SDI quintiles, with higher MIRs observed in lower SDI quintiles.Conclusions: The significantly higher prevalence and incidence rates of AEMT among the older population in high SDI quintiles, compared to lower SDI quintiles, could be attributed to the healthcare overutilization, highlighting the need for policy adjustments.
Studying serum immunoglobulin levels in metabolic dysfunction-associated steatotic liver disease H Abosheaishaa, EAA Hussein, SAB Saleh, M Nassar, A Elmaradny, ... Egyptian Liver Journal 16 (1), 26 , 2026 2026
Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023 S Kim, J Oh, JI Shin, H Aalruz, N Abbas, AE Abdulmalik, RG Aboagye, ... The Lancet Gastroenterology & Hepatology 11 (6), 463-494 , 2026 2026 Citations: 2
Burden of cancer attributable to occupational asbestos exposure in the Americas, 1990–2023: an analysis using the Global Burden of Disease Study 2023 FA Girardi, M Brauer, LM Force, SI Hay, S Spearman, DC Malta, ... The Lancet Regional Health–Americas 58 , 2026 2026 Citations: 1
Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 SB Sirota, RG Bender, RMV Dominguez, A Vongpradith, A Movo, ... The Lancet Neurology 25 (5), 451-468 , 2026 2026
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 SB Sirota, RG Bender, RMV Dominguez, A Movo, LR Swetschinski, ... The Lancet infectious diseases 26 (4), 343-361 , 2026 2026 Citations: 26
The efficacy and safety of cerebral embolic protection devices in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis with trial … A Elazab, AW Hageen, A Elbataa, A Mansour, EE Labeeb, Q Najah, ... Expert Review of Cardiovascular Therapy 24 (3), 253-271 , 2026 2026
Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021 GBD 2021 AEMT Collaborators The Korean Journal of Internal Medicine 41 (2), 350 , 2026 2026
Safety and efficacy of triple combination therapy in hypertension and dyslipidemia: a systematic review and meta-analysis of randomized controlled trials AY Shaban, A Hassan, S Eltawansy, MA Hassan, MT Desouki, N Ahmed, ... The Egyptian Heart Journal 78 (1), 9 , 2026 2026
Global, regional, and national levels and trends in maternal mortality, progress towards the Sustainable Development Goals, and mortality from COVID-19 infection in pregnant … J Faith, I Martopullo, MB Arndt, ID Letourneau, H Aalruz, UO Abaraogu, ... The Lancet Obstetrics, Gynaecology, & Women’s Health , 2026 2026 Citations: 3
Primary Hyperparathyroidism in Pregnancy: Management and Diagnostic Pearls JA Bernier, M Nassar, S Steinmetz-Wood AACE Endocrinology and Diabetes , 2026 2026
Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990–2023: a systematic analysis … LS Flor, CN Spencer, J Cagney, GF Gil, H Aalruz, S Abd ElHafeez, ... The Lancet 407 (10523), 31-52 , 2026 2026 Citations: 10
National-Level Outcomes of Diabetic Ketoacidosis with and without Coma: A Retrospective Analysis of 2.3 Million US Hospitalizations M Nassar, MH Ellabban, MR Murad, O Nassar, N ElSayed ASIDE Internal Medicine 2 (3), 43-54 , 2026 2026
Outcome of Kidney Transplant Patients Following Treatment with Checkpoint Inhibitors: A Case Series AI Kamal, M Reyad, M Keshk, A Daoud, S Vaishnav, M Barakat, A Salas, ... ASIDE Case Reports 2 (1), 15-21 , 2026 2026
The Impact of Chronic Pancreatitis Etiology on Clinical Outcomes: A Population-Based Propensity-Matched Analysis K Elfert, M Abusuliman, M Eldesouki, OT Ahmed, H Abosheaishaa, ... Gastroenterology Research 18 (6), 269 , 2025 2025
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 S Sarah Brooke, RG Bender, RMV Dominguez, A Movo, LR Swetschinski, ... Elsevier , 2025 2025
Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023 Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators Journal of the American College of Cardiology 86 (22), 2167-2243 , 2025 2025 Citations: 272
Global, regional, and national sepsis incidence and mortality, 1990–2021: a systematic analysis AP Gray, E Chung, RL Hsu, DT Araki, AG Hayoon, ND Weaver, ... The Lancet Global Health 13 (12), e2013-e2026 , 2025 2025 Citations: 105
Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease … PB Mark, LK Stafford, ME Grams, H Aalruz, S Abd ElHafeez, AA Abdelgalil, ... The Lancet 406 (10518), 2461-2482 , 2025 2025 Citations: 195
Effect of COVID-19 on Pediatric Population and Congenital Heart Disease: A Comprehensive Examination of Outcomes, Vaccination Effectiveness, and Healthcare Inequalities N Madkour, M Ashour, M Nassar Circulation 152 (Suppl_3), A4370357-A4370357 , 2025 2025 Citations: 1
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational … H Simon I, KL Ong, DF Santomauro, MA Aalipour, H Aalruz, HS Ababneh, ... Elsevier , 2025 2025 Citations: 1
MOST CITED SCHOLAR PUBLICATIONS
Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 M Ng, E Gakidou, J Lo, YH Abate, C Abbafati, N Abbas, M Abbasian, ... The Lancet 405 (10481), 813-838 , 2025 2025 Citations: 1060
Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of … JA Kerr, GC Patton, KI Cini, YH Abate, N Abbas, AHA Abd Al Magied, ... The Lancet 405 (10481), 785-812 , 2025 2025 Citations: 458
Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 M Naghavi, HH Kyu, MA Aalipour, H Aalruz, HS Ababneh, BJ Abafita, ... The Lancet 406 (10513), 1811-1872 , 2025 2025 Citations: 314
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational … SI Hay, KL Ong, DF Santomauro, MA Aalipour, H Aalruz, HS Ababneh, ... The Lancet 406 (10513), 1873-1922 , 2025 2025 Citations: 283
Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023 Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators Journal of the American College of Cardiology 86 (22), 2167-2243 , 2025 2025 Citations: 272
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 LM Force, JM Kocarnik, ML May, K Bhangdia, A Crist, L Penberthy, ... The Lancet 406 (10512), 1565-1586 , 2025 2025 Citations: 268
Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease … PB Mark, LK Stafford, ME Grams, H Aalruz, S Abd ElHafeez, AA Abdelgalil, ... The Lancet 406 (10518), 2461-2482 , 2025 2025 Citations: 195
Diabetes mellitus and COVID-19 M Nassar, A Daoud, N Nso, L Medina, V Ghernautan, H Bhangoo, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (6), 102268 , 2021 2021 Citations: 134
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease … E Haeuser, S Byrne, J Nguyen, C Raggi, SA McLaughlin, C Bisignano, ... The Lancet 406 (10500), 235-260 , 2025 2025 Citations: 132
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for … AE Schumacher, P Zheng, RM Barber, MA Aalipour, H Aalruz, ... The Lancet 406 (10513), 1731-1810 , 2025 2025 Citations: 112
COVID-19 vaccine-induced myocarditis: case report with literature review M Nassar, N Nso, C Gonzalez, S Lakhdar, M Alshamam, M Elshafey, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (5), 102205 , 2021 2021 Citations: 109
Global, regional, and national sepsis incidence and mortality, 1990–2021: a systematic analysis AP Gray, E Chung, RL Hsu, DT Araki, AG Hayoon, ND Weaver, ... The Lancet Global Health 13 (12), e2013-e2026 , 2025 2025 Citations: 105
COVID-19 and autoimmune diseases: a systematic review of reported cases MA Saad, M Alfishawy, M Nassar, M Mohamed, IN Esene, A Elbendary Current rheumatology reviews 17 (2), 193-204 , 2021 2021 Citations: 92
The association between COVID-19 and type 1 diabetes mellitus: A systematic review M Nassar, N Nso, B Baraka, M Alfishawy, M Mohamed, A Nyabera, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (1), 447-454 , 2021 2021 Citations: 87
Gastrointestinal involvement in systemic sclerosis: an updated review M Nassar, V Ghernautan, N Nso, A Nyabera, FC Castillo, W Tu, L Medina, ... Medicine 101 (45), e31780 , 2022 2022 Citations: 86
COVID-19 vaccine induced rhabdomyolysis: case report with literature review M Nassar, H Chung, Y Dhayaparan, A Nyein, BJ Acevedo, C Chicos, ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (4), 102170 , 2021 2021 Citations: 74
Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report J Kong, F Cuevas-Castillo, M Nassar, CM Lei, Z Idrees, WC Fix, ... Journal of Infection and Public Health 14 (10), 1392-1394 , 2021 2021 Citations: 66
CaReL guidelines: A consensus-based guideline on case reports and literature review (CaReL) S Prasad, M Nassar, AY Azzam, F García-Muro-San José, M Jamee, ... Barw Medical Journal , 2024 2024 Citations: 64
COVID-19 mortality in transplant recipients M Alfishawy, A Elbendary, M Mohamed, M Nassar International journal of organ transplantation medicine 11 (4), 145 , 2020 2020 Citations: 54
TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research M Nassar, H Abosheaishaa, K Elfert, A Beran, A Ismail, M Mohamed, ... ASIDE internal medicine 1 (2), 24 , 2025 2025 Citations: 48
